Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by equities research analysts at Leerink Partners from $980.00 to $862.00 in a research note issued on Tuesday.

Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Regeneron Pharmaceuticals in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company’s deep pipeline Monday at the J.P. Morgan Healthcare Conference ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of the National Institutes of Health’s All of Us million-person program ...

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...